According to Eda Cengiz, MD, MHS, FAAP, associate professor of pediatrics at Yale School of Medicine, diabetes management technology is just beginning and can have a positive impact on the daily lives of diabetes patients.
According to Eda Cengiz, MD, MHS, FAAP, associate professor of pediatrics at Yale School of Medicine, diabetes management technology is just beginning and can have a positive impact on the daily lives of diabetes patients.
Transcript (slightly modified)
What’s your outlook on the future of diabetes management technology, including artificial pancreas systems?
This is the beginning of a digital revolution, a diabetes technology revolution, and I think we should be open to this.
When we have 70% to 80% of our patients in poor control, we cannot afford to wait. It’s our duty as clinicians to look for alternative tools to improve diabetes care. No matter what the reason is, people say it’s the compliance or some other issues that result in poor control, it’s our duty to find and implement new tools that our patients will benefit from.
I think a lot of people will like the system but they have to be realistic. This is not the perfect, full, automated, artificial pancreas system. They have to be patient and they have to learn the system and then once they get used to it, once we incorporate new technology and advances into the system, I think they are going to like it better and better. They are going to sleep better, they are going to feel better, they can exercise without any worries, and hopefully it will be the perfect system that will improve our outcomes until we have a cure.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More